Clinical Trials Browser

Phase 3 × OTHER × revumenib × Clear all

NCT06652438 2025-04-04

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute